A discovery reported in Nature Cell Biology from the PCGI Labs of Drs. Roger Greenberg and Junwei Shi addresses the problem of PARP Inhibitor resistance by targeting the ALC1 chromatin remodeler and paving the way for more effective cancer treatments: Click for Press Release. Postdoctoral researcher Priyanka Verma from the Greenberg lab is the first author on this paper.
To respond proactively to a rapidly evolving scientific landscape, Penn investigators working in the areas of DNA repair and cell cycle have joined forces with groups interested in immune signaling, virology, tumor detection/targeting, and hematopoietic stem cells to form the Penn Center for Genome Integrity (PCGI). The overarching mission of this Center is to integrate cutting-edge research in basic and clinical sciences from several key disciplines in order to advance our fundamental understanding of genome integrity and its contributions to human biology. Central to our vision is a mechanism to nucleate outstanding investigators with diverse areas of scientific and clinical expertise across the Penn campus. This should increase cohesion among basic science investigators that would otherwise not frequently interact and promote the development of multi-investigator grants, shared resources, and translation of basic science into the clinic. All of this will promulgate an area of existing excellence at Penn, with the vision of becoming recognized as a world-class center for genome integrity research within the coming years.
Dr. Roger Greenberg and co-Directors Drs. Ben Black and Matthew Weitzman, along with the PCGI core leadership council members, Drs. Michael Lampson, Igor Brodsky, Dennis Discher, Sunny Shin, and Wei Tong, have identified six scientific priority areas that would distinguish the PCGI from related programs at other institutions. These key focus areas include (1) DNA repair, (2) mitotic fidelity, (3) cell cycle control, (4) chromosome biology, (5) immunologic signal transduction and (6) stem cell biology. While the primary mission of this program is fundamental discovery, integration across disciplines coupled with the inclusion of clinical investigators will facilitate translation of basic science advances in cancer, aging, bone marrow failure, autoimmune disease, and host response to pathogens. We have thus constructed provocative questions at the interface of these disciplines as a guiding principle for the Center's research.